US wireless cardiac monitoring companyBioTelemetry Inc. (formerly known as CardioNet) has launched a tender offer to acquire smaller Swiss rival LifeWatch AG. BioTelemetry stated it expects the acquisition to yield efficiencies and "significant synergies" over a period of 12 to 18 months. Assuming the deal had occurred at the start of 2017 with full synergies being realized immediately, the adjusted EBITDA for the combined company in 2017 would be approximately $95-100m.
Nasdaq-listed, Pennsylvania-based BioTelemetry, formerly known as CardioNet, has more than a thousand employees; it recorded sales of $208m in 2016, with operating income of $18m. LifeWatch is a smaller organization...